Phase 2 N=36 Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
Healthy
Primary: Levonorgestrel Pharmacokinetic Profile — 100; 83.3 % of subjects below 175 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=605 Effect of Nutrition Labeling on Fast Food Choices
Healthy
Primary: Total Calories of Meal Ordered
Phase 3 N=266 Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Acne
Primary: The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements — 85; 73 count of participants
Phase 3 N=356 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 77.1; 75.5; 65.3 percentage of participants
N/A N=40 Assessment of the Transferability of Skills From Robotic to Laparoscopic Simulation Platforms
Surgical Simulation Education
Primary: Time to Task Completion (Robotic Task) — 120; 71 seconds
Phase 2 N=380 Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16 — -75.5; -70.5; -67.4; -64.9 Percent change — p=<0.0001
Phase 3 N=167 DFN-02 Open Label Safety Study in Patients With Acute Migraine
Acute Migraine
Primary: Number of Participants With Treatment Emergent Adverse Events — 120 Participants
Phase 2 N=53 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants
Phase 2 N=226 Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Phase 2 N=50 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Liver Neoplasms
Primary: Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria
Phase 3 N=850 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
N/A N=148 Investigation of Sacroiliac Fusion Treatment (INSITE)
Degenerative Sacroiliitis · Sacroiliac Joint Disruption
Primary: Subject Success — 84; 12 Participants
N/A N=45 Evaluation of an Ascensia Blood Glucose Meter and App System
Diabetes Mellitus
Primary: Percent of Responses From Persons Who Performed Each "Software Operations" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree. — 95.4…
Phase 4 N=31 The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function
High Blood Pressure
Primary: Difference in Peak Plasma PAI-1 Level
Phase 4 N=221 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Percentage Change From Baseline (Day 1) of Inflammatory Lesion (IL) Count at Week 4 - Superiority Analysis — -51.9; -38.1 Percent change — p=0.0004